Cellectis receives FDA RMAT designation for blood cancer therapy
Go back to Cellectis receives FDA RMAT designation for blood cancer therapy| (NASDAQ: CLLS) | Delayed: 3.12 +0.08 (2.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.04 | 52 Week High | $37.55 | |||
| Open | $3.12 | 52 Week Low | $16.35 | |||
| Day High | $3.12 | P/E | N/A | |||
| Day Low | $3.12 | EPS | $0.00 | |||
| Volume | 208 | |||||
